IPP Bureau
Ibex Medical Analytics joins forces with HNL Lab Medicine to supercharge AI diagnostics
By IPP Bureau - March 26, 2026
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India
By IPP Bureau - March 26, 2026
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline
By IPP Bureau - March 26, 2026
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
New diabetes drug UBT251 shows strong phase 2 results in China
By IPP Bureau - March 26, 2026
Apollo Hospitals Jubilee Hills breaks robotic surgery records in Telangana, Andhra
By IPP Bureau - March 26, 2026
Doctors at the hospital highlighted that robotic-assisted surgery enhances precision through superior 3D visualisation and improved instrument flexibility
Alkem Laboratories launches affordable semaglutide injection in India
By IPP Bureau - March 26, 2026
Alkem’s semaglutide comes in a pre-filled disposable injection pen containing four doses for a month, priced at Rs. 1,800
Zealand Pharma launches major US research hub in Cambridge, Massachusetts
By IPP Bureau - March 26, 2026
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Nova IVF Fertility expands in Kerala with acquisition of Craft Fertility
By IPP Bureau - March 25, 2026
The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1
Novartis strikes $3 billion deal to acquire next-gen breast cancer drug
By IPP Bureau - March 25, 2026
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
By IPP Bureau - March 25, 2026
Capital infusion to accelerate Earendil’s R&D platform
ImmunityBio scores first Asian approval for ANKTIVA in Macau
By IPP Bureau - March 25, 2026
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain
By IPP Bureau - March 25, 2026
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
Roche inaugurates new research home for the Institute of Human Biology
By IPP Bureau - March 24, 2026
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
Japan okays new long-acting eye drug
By IPP Bureau - March 24, 2026
It promises fewer injections for vision loss patients
